CN102123728B - 用于治疗淀粉样变的化合物 - Google Patents

用于治疗淀粉样变的化合物 Download PDF

Info

Publication number
CN102123728B
CN102123728B CN200980131376.3A CN200980131376A CN102123728B CN 102123728 B CN102123728 B CN 102123728B CN 200980131376 A CN200980131376 A CN 200980131376A CN 102123728 B CN102123728 B CN 102123728B
Authority
CN
China
Prior art keywords
peptide
purposes
medicine
amount
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980131376.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102123728A (zh
Inventor
马库斯·曼德勒
拉德米拉·桑蒂克
哈拉尔德·韦宁格
伊迪思·科皮尼茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of CN102123728A publication Critical patent/CN102123728A/zh
Application granted granted Critical
Publication of CN102123728B publication Critical patent/CN102123728B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN200980131376.3A 2008-06-12 2009-06-12 用于治疗淀粉样变的化合物 Expired - Fee Related CN102123728B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
ATA952/2008 2008-06-12
PCT/AT2009/000235 WO2009149485A2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses

Publications (2)

Publication Number Publication Date
CN102123728A CN102123728A (zh) 2011-07-13
CN102123728B true CN102123728B (zh) 2017-05-31

Family

ID=41401983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980131376.3A Expired - Fee Related CN102123728B (zh) 2008-06-12 2009-06-12 用于治疗淀粉样变的化合物

Country Status (14)

Country Link
US (1) US8409581B2 (https=)
EP (1) EP2310033B1 (https=)
JP (3) JP2011522840A (https=)
KR (1) KR20110036039A (https=)
CN (1) CN102123728B (https=)
AT (2) AT506820B1 (https=)
AU (1) AU2009257168B2 (https=)
BR (1) BRPI0915136A2 (https=)
CA (1) CA2723967A1 (https=)
ES (1) ES2392789T3 (https=)
IL (1) IL209894A (https=)
MX (1) MX2010013657A (https=)
RU (1) RU2491953C2 (https=)
WO (1) WO2009149485A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
CA2828433C (en) 2011-03-16 2020-08-04 Probiodrug Ag Diagnostic antibody assay
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR102460465B1 (ko) * 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
KR102776187B1 (ko) 2015-11-09 2025-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
WO2023159970A1 (zh) * 2022-02-28 2023-08-31 安域生物科技杭州有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
CN101022825A (zh) * 2004-07-13 2007-08-22 阿法里斯研发有限责任公司 预防或治疗阿尔茨海默病的联合疗法及其试剂盒
CN101137394A (zh) * 2004-10-25 2008-03-05 默克制药公司 抗addl抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO1999051254A1 (en) * 1998-04-06 1999-10-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
DE69942274D1 (de) * 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
WO2006136906A2 (en) * 2005-06-17 2006-12-28 Epfl Ecole Polytechnique Fédérale De Lausanne Switch-peptides as tool for the study of fibrillogenesis
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
JP5097695B2 (ja) * 2006-02-22 2012-12-12 株式会社林原 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
CN101022825A (zh) * 2004-07-13 2007-08-22 阿法里斯研发有限责任公司 预防或治疗阿尔茨海默病的联合疗法及其试剂盒
CN101137394A (zh) * 2004-10-25 2008-03-05 默克制药公司 抗addl抗体及其应用

Also Published As

Publication number Publication date
JP5984867B2 (ja) 2016-09-06
AT509611A1 (de) 2011-10-15
US20110171243A1 (en) 2011-07-14
CN102123728A (zh) 2011-07-13
JP2015110588A (ja) 2015-06-18
EP2310033A2 (en) 2011-04-20
IL209894A0 (en) 2011-02-28
IL209894A (en) 2015-08-31
EP2310033B1 (en) 2012-09-05
AU2009257168A1 (en) 2009-12-17
AT506820A1 (de) 2009-12-15
RU2011100125A (ru) 2012-07-20
WO2009149485A2 (en) 2009-12-17
KR20110036039A (ko) 2011-04-06
JP2014139227A (ja) 2014-07-31
AT506820B1 (de) 2011-07-15
MX2010013657A (es) 2011-04-11
BRPI0915136A2 (pt) 2019-09-24
US8409581B2 (en) 2013-04-02
WO2009149485A3 (en) 2010-06-10
RU2491953C2 (ru) 2013-09-10
ES2392789T3 (es) 2012-12-13
CA2723967A1 (en) 2009-12-17
AT509611B1 (de) 2012-04-15
JP5989074B2 (ja) 2016-09-07
JP2011522840A (ja) 2011-08-04
AU2009257168B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
CN102123728B (zh) 用于治疗淀粉样变的化合物
CN102123727B (zh) 用于治疗β-淀粉样变的化合物
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson's disease
HK1152470B (en) Peptides for treating beta-amyloidoses
BRPI0908097B1 (pt) Peptídeo, formulação farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170531

Termination date: 20190612

CF01 Termination of patent right due to non-payment of annual fee